Compared to the aggregate P/E ratio of the 53.15 in the Biotechnology industry, Exelixis Inc. has a lower P/E ratio of 21.12.

In value analysis, though price to earnings (P/E) and price to sales (P/S) are most preferred by investors, the underrated price-to-book ratio (P/B ratio) is also an easy-to-use valuation tool for ...

Nasdaq provides Price/Earnings Ratio (or PE Ratio) and PEG ratio for stock evaluation. Financial analysts and individual investors use PE Ratio and PEG ratios to determine the financial ...

More data is expected to show that its earnings per share (EPS ... capitalization of over $43 billion and a forward price-to-earnings ratio of 39. This valuation makes it highly valued than ...

One common valuation metric for shares is the price-to-earnings (P/E) ratio. Rule of thumb is that the lower it is ... and said it was “expecting to deliver sustainable earnings per share growth”. It ...

Palantir reported earnings per share that were in line with analyst ... The company trades at a price-to-earnings ratio of 561x, and a forward price-to-earnings ratio of 148x.

Rowe Price Gr to report an earnings per share (EPS) of $2.34 ... Rowe Price Gr's debt-to-equity ratio is below the industry average at 0.03, reflecting a lower dependency on debt financing ...